{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 414779406
| IUPAC_name = 6-allyl-5,6,7,8-tetrahydro-4''H''-[1,3]thiazolo[4,5-''d'']azepin-2-amine
| image = Talipexole.svg
| image2 = Talipexole-3D-balls.png
<!--Clinical data-->
| Drugs.com = {{drugs.com|international|talipexole}}
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = Oral
| tradename = Domin
| synonyms = Alefexole
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =
<!--Identifiers-->
| index_label = 
| index2_label =
| IUPHAR_ligand = 5442
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 36085-73-1 
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 5374
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7AM2J46Z1Y
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1289023
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 5181
<!--Chemical data-->
| C=10 | H=15 | N=3 | S=1
| molecular_weight = 209.31 g/mol
| smiles2 = C=CCN1CCC2=C(CC1)SC(=N2)N
| smiles = n1c2c(sc1N)CCN(CC2)C\C=C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = DHSSDEDRBUKTQY-UHFFFAOYSA-N
}}

'''Talipexole''' ('''B-HT920''', '''Domnin''') is a [[dopamine agonist]] that is marketed as a [[antiparkinsonian|treatment for Parkinson's Disease]] in Japan by [[Boehringer Ingelheim]]; it was introduced in 1996.<ref>PharmaLetter 22 July 1996 [http://www.thepharmaletter.com/article/first-launch-in-japan-for-talipexole First Launch In Japan For Talipexole]</ref>  As of December 2014 it was not approved for marketing in the US nor in Europe.<ref>[http://www.evaluategroup.com/Universal/View.aspx?type=Report&id={23D6C352-1933-41D7-A788-054D46E19AAA}&params=%3CPARAMS%20currencyId=%220%22%3E%3CPARAM%20linkKind=%221%22%20compId=%221019%22%20name=%22parkinson%20+disease%22%20itemId=%22125%22%20/%3E%3C/PARAMS%3E EvaluatePharma Database]. Page accessed 9 December 2014</ref>  

Talipexole is a D<sub>2</sub> [[dopamine receptor agonist]] and interacts both pre- and post-synaptic receptors. It also is an  [[Alpha-adrenergic agonist|Î±2-adrenergic agonist]].<ref name=Talipexole>Benkert O, et al. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. {{PMID|8775758}}</ref>

The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.<ref name=Talipexole/>  In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.<ref>Japanese Ministry of Health, Labour and Welfare March 2008 [http://www.pmda.go.jp/english/service/pdf/precautions/PMDSI-245.pdf Pharmaceuticals and Medical Devices Safety Information No. 245]</ref>{{rp|15}}

== References ==
{{Reflist|2}}

{{Antiparkinson}}
{{Adrenergics}}
{{Dopaminergics}}

[[Category:Dopamine agonists]]
[[Category:Alpha-adrenergic agonists]]
[[Category:Allyl compounds]]
[[Category:Thiazoles]]
[[Category:Azepanes]]


{{nervous-system-drug-stub}}